The connection between AR-regulated TMPRSS2 expression and SARS-CoV-2 entry has prompted investigations into whether ADT might confer protection against COVID-19 severity in prostate cancer patients, though results have been inconsistent [19]. The gene discussed is TMPRSS2; the disease is prostate cancer.